Osteopontin is involved in the formation of malignant pleural effusion in lung cancer

Lung Cancer

Volumn 63, Issue 3, 2009, Pages 368-374

  Cui, Ri ^a   Takahashi, Fumiyuki ^a   Ohashi, Rina ^a   Yoshioka, Masakata ^a   Gu, Tao ^a   Tajima, Ken ^a   Unnoura, Takeshi ^a   Iwakami, Shinichiro ^a   Hirama, Michihiro ^a   Ishiwata, Toshiji ^a   Iwase, Akihiko ^a   Takahashi, Kazuhisa ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Lung cancer; Malignant pleural effusion (MPE); Osteopontin; Vascular endothelial growth factor (VEGF)

Indexed keywords

OSTEOPONTIN; SMALL INTERFERING RNA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CANCER CELL CULTURE; CANCER GROWTH; CELL STRAIN; CONTROLLED STUDY; ENDOTHELIUM CELL; IN VITRO STUDY; KNOCKOUT MOUSE; LUNG CANCER; LUNG CARCINOGENESIS; MALE; MALIGNANT TRANSFORMATION; MESOTHELIUM; MOUSE; NONHUMAN; PLEURA CAVITY; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; UMBILICAL VEIN;

ANIMALS; BLOTTING, NORTHERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OSTEOPONTIN; PLEURAL EFFUSION, MALIGNANT; RNA, NEOPLASM; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59249103184     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.06.020     Document Type: Article

References (30)

1. Yano S., Herbst R.S., Shinohara H., Knighton B., Bucana C.D., Killion J.J., et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 6 (2000) 957-965
2. Sugiura S., Ando Y., Minami H., Ando M., Sakai S., and Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3 (1997) 47-50
3. Naito T., Satoh H., Ishikawa H., Yamashita Y.T., Kamma H., Takahashi H., et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 17 (1997) 4743-4746
4. Hausheer F.H., and Yarbro J.W. Diagnosis and treatment of malignant pleural effusion. Semin Oncol 12 (1985) 54-75
5. Light R.W., and Vargas F.S. Pleural sclerosis for the treatment of pneumothorax and pleural effusion. Lung 175 (1997) 213-223
6. Carmeliet P., Ferreira V., Breier G., Pollefeyt S., Kieckens L., Gertsenstein M., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
7. Ferrara N., Carver-Moore K., Chen H., Dowd M., Lu L., O'Shea K.S., et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380 (1996) 439-442
8. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., and Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
9. Ferrara N., and Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS 79 (1997) 209-232
10. Kiriakidis S., Andreakos E., Monaco C., Foxwell B., Feldmann M., and Paleolog E. VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinase-defective form of the IkappaB kinase 2. J Cell Sci 116 (2003) 665-674
11. Yano S., Shinohara H., Herbst R.S., Kuniyasu H., Bucana C.D., Ellis L.M., et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am J Pathol 157 (2000) 1893-1903
12. Matsumori Y., Yano S., Goto H., Nakataki E., Wedge S.R., Ryan A.J., et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 16 (2006) 15-26
13. Yanagawa H., Takeuchi E., Suzuki Y., Ohmoto Y., Bando H., and Sone S. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48 (1999) 396-400
14. Zebrowski B.K., Yano S., Liu W., Shaheen R.M., Hicklin D.J., Putnam J.B., et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 5 (1999) 3364-3368
15. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77 (1999) 527-543
16. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13 (1999) 9-22
17. Senger D.R., Ledbetter S.R., Claffey K.P., Papadopoulos-Sergiou A., Peruzzi C.A., and Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149 (1996) 293-305
18. Shijubo N., Kojima H., Nagata M., Ohchi T., Suzuki A., Abe S., et al. Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60 (2003) 186-198
19. Cui R., Takahashi F., Ohashi R., Gu T., Yoshioka M., Nishio K., et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer 57 (2007) 302-310
20. Donati V., Boldrini L., Dell'Omodarme M., Prati M.C., Faviana P., Camacci T., et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 11 (2005) 6459-6465
21. Hu Z., Lin D., Yuan J., Xiao T., Zhang H., Sun W., et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11 (2005) 4646-4652
22. Elsammak M.M., Morsi T.S., Khamis H.I., Ragab M.S., Zaki M.A., Abdel-Hadi M., et al. Osteopontin and C-reactive protein in Egyptian patients affected with tuberculous and malignant pleural effusion. Ann Clin Biochem 44 (2007) 264-272
23. Stathopoulos G.T., Zhu Z., Everhart M.B., Kalomenidis I., Lawson W.E., Bilaceroglu S., et al. Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34 (2006) 142-150
24. Kraft A., Weindel K., Ochs A., Marth C., Zmija J., Schumacher P., et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85 (1999) 178-187
25. Gary Lee Y.C., Melkerneker D., Thompson P.J., Light R.W., and Lane K.B. Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med 165 (2002) 88-94
26. Adya R., Tan B.K., Punn A., Chen J., and Randeva H.S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res (2007)
27. Xu H., Czerwinski P., Hortmann M., Sohn H.Y., Forstermann U., and Li H. Protein kinase C {alpha} promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovasc Res (2007)
28. Sahn S.A. State of the art The pleura. Am Rev Respir Dis 138 (1988) 184-234
29. Takahashi F., Akutagawa S., Fukumoto H., Tsukiyama S., Ohe Y., Takahashi K., et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 98 (2002) 707-712
30. Tang H., Wang J., Bai F., Hong L., Liang J., Gao J., et al. Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochem Cell Biol 85 (2007) 103-110